Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Pronged antibody head off a bone marrow cancer before it starts?

NCT ID NCT06745687

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests an experimental drug called CM-336 in people with high-risk smoldering multiple myeloma, a condition that often leads to active cancer. The drug is a bispecific antibody designed to guide immune cells to destroy myeloma cells. Researchers want to see if it can make cancer cells undetectable and delay or prevent the disease from progressing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental bispecific antibody called CM-336 that targets BCMA and CD3 proteins
What this could lead to
If successful, this could offer a way to delay or prevent smoldering multiple myeloma from progressing to active disease, potentially reducing the need for intensive chemotherapy.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The drug may cause side effects such as immune reactions or infections, and it is not yet proven to work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK SMOLDERING MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK SMOLDERING MULTIPLE MYELOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences

    RECRUITING

    Tianjin, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.